Skip to content
site-logo

QLeaR Advisors

Help with Compliance for Small to Mid-Sized Businesses.

  • Home
  • Meet Us.
    • Our Partners.
  • Our Specialties.
  • Brag Book.
  • Our Blog.
  • Let’s Connect.
  • Home
  • Meet Us.
    • Our Partners.
  • Our Specialties.
  • Brag Book.
  • Our Blog.
  • Let’s Connect.
Tips & Advice

How the FDA Warning Letter to Young Living Essential Oils should influence Influencer Marketing

How the FDA Warning Letter to Young Living Essential Oils should influence Influencer Marketing

A warning letter published on July 19th, 2022 by the FDA to Young Living Essential Oils names not only the company but also individual consultants within its multi-level marketing organization (find it below). The FDA used specific statements from each individual’s social media accounts (usually Instagram) to make its case. In our research, this is the first time individual contracted agents have been named in a warning letter. This evolution in strategy from the FDA sends a clear message to sales agents as well as people operating in this gray area of “influencer marketing” that their public activities may result in formal regulatory actions and could lead to personal liability.

This was at least the second time Young Living has encountered issues with the FDA, receiving another warning from the FDA in 2014. Since that time, there have been several OTC drugs manufactured/distributed by Young Living registered with the FDA (e.g. Salicylic acid in their Acne Treatment). In addition, there is an interesting and informative FAQ (find it below) detailed with specific guidance on how to avoid making false claims about the products being sold. It didn’t work.

Warning Letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/young-living-essential-oils-corporate-615777-06102022

FAQ: https://static.youngliving.com/en-US/PDFS/Sharing%20Young%20Living%20the%20Right%20Way%20FAQ.pdf

FTC: https://www.ftc.gov/news-events/topics/truth-advertising

SHARE THIS
Jackie Torfin - CEO and Principal Advisor for QLeaR Advisors

About Jackie Torfin

Jackie has over 30 years experience and deep expertise in quality, regulatory, pre-clinical and clinical compliance. She has served in Senior Global roles for companies including Beckman Coulter, NAMSA, CIMA Labs, PDL BioPharma, Arizant/3M, and Heraeus.

More articles by Jackie Torfin

Post navigation

The Fallacy of the “Original Paper Record”
The 12 Days of Quality

Recent Posts

  • Printing Electronic Data Doesn’t Solve Data Integrity Issues—Here’s Why
  • Why the FDA’s LDT Rule Was Necessary—Even If the Court Disagreed
  • International Women’s Day – This One’s for the Girls!
  • From Team Member to Team Leader: Navigating the Challenges of Management
  • Training Effectiveness vs. Training Competence: Understanding the Nuances

Categories

  • Blog
  • Brag Book
  • Compliance
  • FDA
  • Leadership
  • Lifestyle
  • Management
  • Musings
  • Quality
  • Tips & Advice
  • Training

About Us

Welcome to QLeaRadvisors.com, your premier destination for compliance consulting services. Managed by Embossed Marketing, our website is dedicated to providing high-quality information connections and support to clients worldwide.

  • Home
  • Meet Us.
  • Our Partners.
  • Our Specialties.
  • Brag Book.
  • Our Blog.
  • Let’s Connect.
  • Terms & Conditions
  • Privacy Policy
Copyright © 2025 | All Rights Reserved | Website by Embossed Marketing
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are alright with this. To learn more, read our Privacy policy.Ok